Conmed Corporation announced the departure of Todd Garner from his role as chief financial officer (CFO), effective March 15, 2026. Garner will stay with the company in an advisory capacity through November 2, 2026.

The company has begun a comprehensive search process, supported by a leading executive search firm, to identify its next CFO.

“On behalf of our Board and leadership team, I want to thank Todd for his many contributions to CONMED over the past eight years,” said Pat Beyer, Conmed’s president and CEO. “Todd has been instrumental in strengthening our financial foundation and supporting strategic initiatives that position CONMED for scalable, long-term growth. We are also grateful for his commitment to ensuring a seamless transition.”

The company reaffirmed its full-year 2025 consolidated revenue and adjusted EPS guidance on November 5, 2025. Garner’s planned departure isn’t the result of a disagreement regarding Conmed’s financial statements or disclosures, the company said.

“I am grateful to my CONMED colleagues over the past eight years. It has been rewarding to be part of such a high-quality, driven team that has dramatically improved the revenue growth and profitability of the company. I’m committed to a smooth transition, positioning CONMED for strong future success,” said Garner.

Last month, the company announced its intent to exit its gastroenterology product lines as part of a strategy to optimize its portfolio.